Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
ESMO Open ; 9(4): 102996, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38613911

ABSTRACT

BACKGROUND: Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who received one or more prior systemic treatments. However, the median progression-free survival (mPFS) is ∼4 months, and little is known about the possibility of administering subsequent therapies, their efficacy, and clinicopathological determinants of outcome. METHODS: A real-world dataset including patients with BRAFV600E-mutated mCRC treated with TT at 21 Italian centers was retrospectively interrogated. We assessed treatments after progression, attrition rates, and outcomes. RESULTS: Of the 179 patients included, 85 (47%), 32 (18%), and 7 (4%) received one, two, or three lines of treatment after TT, respectively. Those receiving TT in the second line were more likely to receive at least one subsequent therapy (53%), as compared with those treated with TT in the third line or beyond (30%; P < 0.0001), and achieved longer postprogression survival (PPS), also in a multivariate model (P = 0.0001). Among 62 patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors receiving one or more lines of treatment after second-line TT, combinatory chemotherapy ± anti-vascular endothelial growth factor (anti-VEGF) was associated with longer PFS and PPS as compared with trifluridine-tipiracil or regorafenib (mPFS: 2.6 versus 2.0 months, P = 0.07; PPS: 6.5 versus 4.4 months, P = 0.04). CONCLUSIONS: Our real-world data suggest that TT should be initiated as soon as possible after the failure of first-line treatment in BRAFV600E-mutated mCRC. Among patients with pMMR/MSS tumors, combinatory chemotherapy ± anti-VEGF appears the preferred treatment choice after TT failure.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Carbamates , Cetuximab , Colorectal Neoplasms , Mutation , Proto-Oncogene Proteins B-raf , Sulfonamides , Humans , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Cetuximab/therapeutic use , Cetuximab/pharmacology , Male , Female , Proto-Oncogene Proteins B-raf/genetics , Middle Aged , Retrospective Studies , Aged , Carbamates/therapeutic use , Carbamates/pharmacology , Sulfonamides/therapeutic use , Sulfonamides/pharmacology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Disease Progression , Progression-Free Survival , Adult , Aged, 80 and over , Neoplasm Metastasis , Italy
2.
Acta Otorhinolaryngol Belg ; 52(1): 55-7, 1998.
Article in English | MEDLINE | ID: mdl-9581198

ABSTRACT

The cystoadenolymphoma or Warthin's tumor is a benign lesion of the salivary glands and principally of the parotid gland. We report a case of a 62 year old white male seen at our Institute for evaluation of an asymptomatic right neck mass located 2 cm below the mandible at the anterior margin of the sternocleidomastoid muscle. The echography showed a lymphoid structure simulating a lymphoproliferative process. Histologic examination of the surgical specimen revealed a Warthin's tumor. We discuss the importance of considering Warthin's tumor in the differential diagnosis of an isolated neck mass, and report our experience over a ten year period in the surgical management of neck masses. Additionally, the literature concerning extraparotid Warthin's tumors is reviewed.


Subject(s)
Adenolymphoma/pathology , Head and Neck Neoplasms/pathology , Diagnosis, Differential , Humans , Male , Middle Aged
3.
Rhinology ; 31(3): 139-41, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8256084

ABSTRACT

A rare case of cholesterol granuloma of the frontal sinus is reported. The pathogenetical mechanisms and the tumour's behaviour are discussed on the basis of the patient's, the radiologic examination and the pathologist's finding's. A follow-up of three years is given.


Subject(s)
Cholesterol , Frontal Sinus , Granuloma, Foreign-Body , Aged , Aged, 80 and over , Female , Granuloma, Foreign-Body/diagnostic imaging , Granuloma, Foreign-Body/pathology , Humans , Paranasal Sinus Diseases/diagnostic imaging , Paranasal Sinus Diseases/pathology , Radiography
SELECTION OF CITATIONS
SEARCH DETAIL
...